Safety Trial of Herbal Melanin in Gastritis Patients

NCT ID: NCT03428568

Last Updated: 2018-02-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 132 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-31
• Study Completion Date: 2020-03-31

Brief Summary

The aim of the study is to use Melanole, a herbal extract from Nigella sativa, for treatment of gastritis. The effect of Melanole will be compared between participants (including H. pylori and non-H.pylori infected patients), with the triple therapy and Standard of care treatment of gastritis, respectively.

All participants will be examined before and after the administration of Melanole. The results showing a relief of gastritis symptoms for non-H. pylori patients and partial or complete eradication of H. pylori for H.pylori infected patients will be evaluated.

Detailed Description

Background:

The melanin to be used in this study is a herbal melanin (HM) that has been extracted from the plant Nigella sativa. Nigella sativa was obtained from local market in Riyadh, Saudi Arabia. HM has been obtained from seed total powdered extract using standard extraction procedure and has been reported as a patent for the first time.The percentage of pure melanin in total Nigella sativa L. is 9% as identified using Electron Spin Resonance (ESR) and Fourier Transform- Infra Red (FI-IR) and calculated using wet chemical methods. Three different patches of Nigella sativa L that were obtained from different Nigella sativa L species were tested (Saudi, Ethiopian and Indian) and the same percentage of HM was obtained. The safety of HM has been tested and confirmed by different labs including lab for Quality and Safety and Industrial Research Institute(IRI) (see supplements 1 and 2). Similarly, the safety of the HM capsules have been tested at the Toxicology and Bioanalysis in King Faisal Specialist Hospital(KFSH) (see supplement 3). Moreover, the capsules have been approved and certified for free sale by the Ministry of Health at Lebanon.

Study Area:

The study will be performed in the gastroenterology clinic at National Guard Health Affairs(NGHA). Volunteers who participate in the study will be recruited from NGHA clinics. Participates are patients diagnosed with gastritis, both H. Pylori and non-H.Pylori infected, together with healthy volunteers.

The histological studies will be performed at the pathology department at NGHA.

Taking biopsies during endoscopy:

The best way to get tissue samples from the stomach is through a procedure called an esophagogastroduodenoscopy. It is more commonly known as an endoscopy or EGD. This is generally done as an outpatient procedure. The biopsies will be taken through the esophagogastroduodenoscopy (EGD) by a ultra-thin forceps, then will be saved in special container and send to the Laboratory for staining and microscopic examination. Under the microscope the pathologist will look for the abnormal mucosa , inflammation, ulceration , and helicobacter pylori gram negative micro-organism .During the procedure there is low chance of some complications which happened in 1: 10 000 , these include ; injury to the mucosa with bleeding and perforation , discomfort , sedation related complication like headache and nausea . These rare but the patient will be informed about it.

Study Subjects:

Patients with gastritis or showing gastritis symptoms will be enrolled in this study. Gastritis participate patients will be selected after detection of gastric lesions by undergoing routine diagnostic tests (such as endoscopy of upper digestive system).

Sample Size Calculation and Estimation:

The sample size has been estimated as 132 ( 22 subjects per group). The calculation and estimation have been done as follows:

Sample Size Calculation

The calculation of sample size was performed using Query Advisor V.7

Sample Size Estimated

The minimum number of Subjects needed in each group is 18, a two sided 95.0% confidence interval for the difference between a Group 1 proportion of 0.6 and Group 2 proportion of 0.2 based on the large sample normal approximation will extend 0.3 from the observed differences in proportions. The total required sample would be (6 groups x 18=108).The assumed withdrawal/dropout rate is 20% in each group (22 subjects per group), the final sample size would ne 132 subjects. The calculation of sample size was performed using Query Advisor V.7)

Data Collection method:

All data will be collected electronically and reported in Case Report Forms.

Data Cleaning:

Raw data will be processed in accordance with the best practices for raw data management to identify any inaccuracies or incompleteness in advance to the statistical analysis. In order to accomplish this task, all interval variables will be checked and summarized in terms of maximum and minimum values. Minimum and maximum values will be checked and compared against the nominal maximum and minimum value of each variable and variables with implausible values will be flagged. A similar process will be applied to categorical variables to identify any potential anomalies (miscode) by running a general frequency analysis.

Cohort Characterization:

All variables will be summarized and reported using descriptive statistics. Interval variables will be summarized and reported in terms of mean and standard deviation. Categorical variables will be summarized and reported in terms of frequency distribution. All variables will be compared across study groups using chi square and t test accordingly.

Primary Outcome(s) Analysis:

Chi square test will be used to compare the distribution of gastritis across the study groups. Results will be reported in terms of count, percent, and p-value. Significance will be declared at alfa less than 0.05. Binary logistic regression will be used to identify significant predictors of the primary outcomes. The statistical model will include key variables that showed significance with the primary outcome at the bivariate level. Results will be reported in terms of odds ratio, std. error, 95% confidence interval, and p-value. Significance will be declared at alfa less than 0.05.

Intent to treat analysis will be the approach in analyzing the data.

Statistical Analytical System(SAS) 9.2 will be used for all statistical analyses.

Conditions

Acid Dyspepsia; Gastritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Herbal Melanin

Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)

Group Type: EXPERIMENTAL

Herbal Melanin

Intervention Type: OTHER

Herbal melanin extracted from Nigella sativa seeds

Nexium

omeprazole 40 mg once per day for one month.

Group Type: ACTIVE_COMPARATOR

Nexium

Intervention Type: DRUG

omeprazole

H-Pylori infected : Herbal Melanin

Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)

Group Type: EXPERIMENTAL

Herbal Melanin

Intervention Type: OTHER

Herbal melanin extracted from Nigella sativa seeds

nexium+ amoxil+clarithromycin

omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.

Omeprazole+Amoxil+clarithromycin is the standard triple therapy given

Group Type: ACTIVE_COMPARATOR

Nexium

Intervention Type: DRUG

omeprazole

Amoxil

Intervention Type: DRUG

Antibiotic

Clarithromycin

Intervention Type: DRUG

Antibiotic

nexium +Herbal melanin

omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested

Group Type: EXPERIMENTAL

Herbal Melanin

Intervention Type: OTHER

Herbal melanin extracted from Nigella sativa seeds

Nexium

Intervention Type: DRUG

omeprazole

Herbal melanin+amoxil+ clarithromycin

Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested

Group Type: EXPERIMENTAL

Herbal Melanin

Intervention Type: OTHER

Herbal melanin extracted from Nigella sativa seeds

Amoxil

Intervention Type: DRUG

Antibiotic

Clarithromycin

Intervention Type: DRUG

Antibiotic

Interventions

Herbal Melanin

Herbal melanin extracted from Nigella sativa seeds

Intervention Type: OTHER

Nexium

omeprazole

Intervention Type: DRUG

Amoxil

Antibiotic

Intervention Type: DRUG

Clarithromycin

Antibiotic

Intervention Type: DRUG

Other Intervention Names

Melanole; Aciloc; Klacid

Eligibility Criteria

Inclusion Criteria

• Males or Females between 18- 60 years
• Willing to sign Informed Consent Form (ICF)
• Women of Child bearing age will be asked to conduct a pregnancy test before enrolling in the study and offered contraceptives for the duration of the study participation
• Clinical Pictures of Gastritis.
• Histologically confirmed H- Pylori Gastritis or Non H- Pylori by one week from enrollment.

Exclusion Criteria

• Patients with disturbed gastrointestinal physiology (gastric surgery, vagotomy, Zollinger-Ellison syndrome)
• Patients who have been treated with proton pump inhibitors during 3 weeks prior to inclusion
• Patients who have been treated with antibiotics or bismuth containing drugs 1 month prior enrolling in the study
• Patient with pyloric stenosis
• Patient with Hematologic disorder
• Patient with congestive heart disease
• Women who are pregnant or lactating
• Current or past history of malignancy
• Drug abuser and chronic alcoholism
• Patients currently participating in any other clinical trial of any kind

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

King Abdullah International Medical Research Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adila SA Elobeid, PhD

Role: PRINCIPAL_INVESTIGATOR

Ministry of National Guard

Central Contacts

Adila SA Elobeid, PhD

Role: CONTACT

adilasalihelobeid@gmail.com

+966553543096

khizra sultana, Masters

Role: CONTACT

khizzy31@gmail.com

+966542403883

References

El-Obeid A, Al-Harbi S, Al-Jomah N, Hassib A. Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production. Phytomedicine. 2006 May;13(5):324-33. doi: 10.1016/j.phymed.2005.03.007. Epub 2005 Sep 19.

Reference Type: BACKGROUND

PMID: 16635740 (View on PubMed)

Biotechnological Method for Production of Melanin Pigments. Patent, award by Swedish PRV Patent office-Stockholm 2011 and United Nations PCT-WIPO 2011. Registered in US &Canada

Reference Type: BACKGROUND

Extraction of melanin from Nigella sativa L. Patent No. 451, Khartoum, Sudan. 1998.

Reference Type: BACKGROUND

Tortora, G.J. and Grabowski, S.R. (2003). Principles of Anatomy and Physiology. 10th ed. John Wiley& Sons, Inc, NJ, p.889.).

Reference Type: BACKGROUND

Parkin DM. International variation. Oncogene. 2004 Aug 23;23(38):6329-40. doi: 10.1038/sj.onc.1207726.

Reference Type: BACKGROUND

PMID: 15322508 (View on PubMed)

Peleteiro B, Bastos A, Ferro A, Lunet N. Erratum to: Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage. Dig Dis Sci. 2015 Sep;60(9):2849. doi: 10.1007/s10620-015-3779-5. No abstract available.

Reference Type: BACKGROUND

PMID: 26160435 (View on PubMed)

Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol. 2014 Feb 14;20(6):1450-69. doi: 10.3748/wjg.v20.i6.1450.

Reference Type: BACKGROUND

PMID: 24587621 (View on PubMed)

Hawkins C, Hanks GW. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature. J Pain Symptom Manage. 2000 Aug;20(2):140-51. doi: 10.1016/s0885-3924(00)00175-5.

Reference Type: BACKGROUND

PMID: 10989252 (View on PubMed)

El-Tahir, K. E. H.; Hassib, A. M.; El-Hag, H.; Ponten, F.; Westermark, B. El- Obeid Adila (2009). Anti-ulcerogenic effects of Nigella sativa Melanin. Sudan Patent No. 1683.

Reference Type: BACKGROUND

Mimura T, Maeda K, Tsujibo H, Satake M, Fujita T. Studies on biological activities of melanin from marine animals. II. Purification of melanin from Octopus vulgaris Cuvier and its inhibitory activity on gastric juice secretion in rats. Chem Pharm Bull (Tokyo). 1982 Apr;30(4):1508-12. doi: 10.1248/cpb.30.1508. No abstract available.

Reference Type: BACKGROUND

PMID: 7105266 (View on PubMed)

Mimura T, Maeda K, Terada T, Oda Y, Morishita K, Aonuma S. Studies on biological activities of melanin from marine animals. III. Inhibitory effect of SM II (low molecular weight melanoprotein from squid) on phenylbutazone-induced ulceration in gastric mucosa in rats, and its mechanism of action. Chem Pharm Bull (Tokyo). 1985 May;33(5):2052-60. doi: 10.1248/cpb.33.2052. No abstract available.

Reference Type: BACKGROUND

PMID: 4053227 (View on PubMed)

El-Dakhakhny M, Barakat M, El-Halim MA, Aly SM. Effects of Nigella sativa oil on gastric secretion and ethanol induced ulcer in rats. J Ethnopharmacol. 2000 Sep;72(1-2):299-304. doi: 10.1016/s0378-8741(00)00235-x.

Reference Type: BACKGROUND

PMID: 10967486 (View on PubMed)

Kanter M, Demir H, Karakaya C, Ozbek H. Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. World J Gastroenterol. 2005 Nov 14;11(42):6662-6. doi: 10.3748/wjg.v11.i42.6662.

Reference Type: BACKGROUND

PMID: 16425361 (View on PubMed)

Seniuk OF, Gorovoj LF, Beketova GV, Savichuk HO, Rytik PG, Kucherov II, Prilutskay AB, Prilutsky AI. Anti-infective properties of the melanin-glucan complex obtained from medicinal tinder bracket mushroom, Fomes fomentarius (L.: Fr.) Fr. (Aphyllophoromycetideae). Int J Med Mushrooms. 2011;13(1):7-18. doi: 10.1615/intjmedmushr.v13.i1.20.

Reference Type: BACKGROUND

PMID: 22135899 (View on PubMed)

Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:21-5. doi: 10.1046/j.1365-2036.11.s1.4.x.

Reference Type: BACKGROUND

PMID: 9146787 (View on PubMed)

Salem EM, Yar T, Bamosa AO, Al-Quorain A, Yasawy MI, Alsulaiman RM, Randhawa MA. Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. Saudi J Gastroenterol. 2010 Jul-Sep;16(3):207-14. doi: 10.4103/1319-3767.65201.

Reference Type: BACKGROUND

PMID: 20616418 (View on PubMed)

Poelmans J, Feenstra L, Demedts I, Rutgeerts P, Tack J. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol. 2004 Aug;99(8):1419-26. doi: 10.1111/j.1572-0241.2004.30066.x.

Reference Type: BACKGROUND

PMID: 15307853 (View on PubMed)

Poelmans J, Tack J, Feenstra L. Chronic middle ear disease and gastroesophageal reflux disease: a causal relation? Otol Neurotol. 2001 Jul;22(4):447-50. doi: 10.1097/00129492-200107000-00005.

Reference Type: BACKGROUND

PMID: 11449097 (View on PubMed)

Poelmans J, Feenstra L, Tack J. Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms. Dig Dis Sci. 2006 Feb;51(2):282-8. doi: 10.1007/s10620-006-3126-y.

Reference Type: BACKGROUND

PMID: 16534670 (View on PubMed)

Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005 Jun;295(3):179-85. doi: 10.1016/j.ijmm.2005.02.009.

Reference Type: BACKGROUND

PMID: 16044857 (View on PubMed)

Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Muller-Hermelink HK, Eck M. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 2004 Jun;136(3):521-6. doi: 10.1111/j.1365-2249.2004.02464.x.

Reference Type: BACKGROUND

PMID: 15147355 (View on PubMed)

El-Obeid A, Hassib A, Ponten F, Westermark B. Effect of herbal melanin on IL-8: a possible role of Toll-like receptor 4 (TLR4). Biochem Biophys Res Commun. 2006 Jun 16;344(4):1200-6. doi: 10.1016/j.bbrc.2006.04.035. Epub 2006 May 2.

Reference Type: BACKGROUND

PMID: 16650380 (View on PubMed)

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004 Jul 23;118(2):229-41. doi: 10.1016/j.cell.2004.07.002.

Reference Type: BACKGROUND

PMID: 15260992 (View on PubMed)

Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology. 2006 Sep;131(3):862-77. doi: 10.1053/j.gastro.2006.06.017.

Reference Type: BACKGROUND

PMID: 16952555 (View on PubMed)

Zheng L, Riehl TE, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology. 2009 Dec;137(6):2041-51. doi: 10.1053/j.gastro.2009.08.055. Epub 2009 Sep 2.

Reference Type: BACKGROUND

PMID: 19732774 (View on PubMed)

Hoogerwerf et al. 2006. Hoogerwerf, W.J., Pasricha, P.J., 2006. Pharmacotherapy of gastric acidity,peptic ulcer and gastroesophageal reflux disease: Goodman and Gilman's.The pharmacological basis of therapeutics. McGraw-Hill, United States, pp.869-882).

Reference Type: BACKGROUND

Wada A, Ogushi K, Kimura T, Hojo H, Mori N, Suzuki S, Kumatori A, Se M, Nakahara Y, Nakamura M, Moss J, Hirayama T. Helicobacter pylori-mediated transcriptional regulation of the human beta-defensin 2 gene requires NF-kappaB. Cell Microbiol. 2001 Feb;3(2):115-23. doi: 10.1046/j.1462-5822.2001.00096.x.

Reference Type: BACKGROUND

PMID: 11207625 (View on PubMed)

Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002 Nov 1;298(5595):1025-9. doi: 10.1126/science.1075565.

Reference Type: BACKGROUND

PMID: 12411706 (View on PubMed)

Ohara T, Morishita T, Suzuki H, Masaoka T, Nagata H, Hibi T. Pathophysiological role of human beta-defensins 2 in gastric mucosa. Int J Mol Med. 2004 Dec;14(6):1023-7.

Reference Type: BACKGROUND

PMID: 15547668 (View on PubMed)

Other Identifiers

RC15/152/R

Identifier Type: -

Identifier Source: org_study_id